Stockreport

GlaxoSmithKline's Nucala Success, And Other News: The Good, Bad And Ugly Of Biopharma [Seeking Alpha]

GlaxoSmithKline PLC  (GSK) 
US:NYSE Investor Relations: gsk.com/en-gb/investors
PDF SummaryGlaxoSmithKline's Nucala met its primary endpoint in a pivotal study.Incyte reported positive data from a phase 3 trial of Ruxolitinib.XBiotech shot up on plasma [Read more]